OR DFR Bulletin 2026-02: Withdrawal of Bulletin DFR 2024-3

350 Winter St. NE, Rm 410, PO Box 14480, Salem, OR 97309 503-947-7694 dfr.oregon.gov 1 Oregon Department of Consumer and Business Services Division of Financial Regulation, Bulletin No. DFR 2026-2   To: All manufacturers of prescription drugs subject to Oregon Drug Price Transparency Program Date: February 13, 2026 RE: Withdrawal of Bulletin DFR 2024-3 I. Purpose: This bulletin withdraws Bulletin DFR 2024-3 re: Suspension of requirement to file certain annual price increase reports. II. Authority:  ORS 646A.689  Pharm. Research & Manufacturers of Am. v. Stolfi, 153 F4th 795 (9th Cir 2025) III. Guidance: Bulletin DFR 2024-3 provided guidance to prescription drug manufacturers subject to the Oregon Drug Price Transparency Program regarding a 2024 U.S. District Court ruling that resulted in the indefinite suspension of the program’s annual price increase reporting. Subsequently, the Ninth Circuit Court of Appeals issued a ruling effective October 31, 2025 overturning that decision. Accordingly, the department must resume collection of mandatory price increase reports from manufacturers and Bulletin DFR 2024-3 is hereby withdrawn. This bulletin is effective upon issuance. ______________________________________ __________________________ TK Keen, Administrator Date Insurance Commissioner Division of Financial Regulation 2/13/2026